MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company Total Assets 2011-2026 | BMY
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90 B | 92.6 B | 95.2 B | 96.8 B | 109 B | 118 B | 130 B | 35 B | 33.6 B | 33.7 B | 31.7 B | 33.7 B | 38.6 B | 35.9 B | 33 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 130 B | 31.7 B | 67.2 B |
Quarterly Total Assets Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94.7 B | 92.4 B | 93.7 B | 94.6 B | 99 B | 91.3 B | 93.5 B | 94.3 B | 96.8 B | 98.2 B | - | 103 B | 109 B | 111 B | 111 B | 112 B | 118 B | 118 B | 118 B | 118 B | 130 B | 130 B | 130 B | 130 B | 35 B | 35 B | 35 B | 35 B | 33.6 B | 33.6 B | 33.6 B | 33.6 B | 33.7 B | 33.7 B | 33.7 B | 33.7 B | 31.7 B | 31.7 B | 31.7 B | 31.7 B | 33.7 B | 33.7 B | 33.7 B | 33.7 B | 38.6 B | 38.6 B | 38.6 B | 38.6 B | 35.9 B | 35.9 B | 35.9 B | 35.9 B | 33 B | 33 B | 33 B | 33 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 130 B | 31.7 B | 65.3 B |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
258 M | $ 28.46 | 3.45 % | $ 319 M |  USA |
 |
Ascendis Pharma A/S
ASND
|
1.3 B | $ 221.88 | -0.87 % | $ 5 B |  Danmark |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Axsome Therapeutics
AXSM
|
690 M | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Galera Therapeutics
GRTX
|
7.2 M | - | -32.59 % | $ 7.61 M | USA |
 |
Pharming Group N.V.
PHAR
|
215 M | $ 15.36 | -0.71 % | $ 7.59 B |  Niderland |
 |
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.37 | -4.2 % | $ 350 M |  Britain |
 |
Kamada Ltd.
KMDA
|
379 M | $ 8.5 | -1.39 % | $ 260 M |  Israel |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B |  France |
 |
Benitec Biopharma
BNTC
|
99.6 M | $ 10.98 | -4.52 % | $ 452 M | USA |
 |
Inventiva S.A.
IVA
|
119 M | $ 5.78 | -4.3 % | $ 138 M | France |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | France |
 |
Compugen Ltd.
CGEN
|
157 M | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Tiziana Life Sciences PLC
TLSA
|
11.3 M | $ 1.21 | -3.97 % | $ 71.5 M | Britain |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
PainReform Ltd.
PRFX
|
4.52 M | $ 2.28 | -0.44 % | $ 1.03 M | Israel |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
|
Foghorn Therapeutics
FHTX
|
198 M | $ 5.0 | 2.25 % | $ 315 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
AbCellera Biologics
ABCL
|
1.36 B | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
7.59 B | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Curis
CRIS
|
41.3 M | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
7.94 M | - | -74.18 % | $ 955 K | USA |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
Coherus BioSciences
CHRS
|
258 M | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 7.7 | -5.87 % | $ 1.29 B | Britain |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Cellectis S.A.
CLLS
|
325 M | $ 3.34 | -4.02 % | $ 116 M | France |
 |
Arbutus Biopharma Corporation
ABUS
|
144 M | $ 4.24 | -2.97 % | $ 704 M | Canada |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cardiff Oncology
CRDF
|
61.9 M | $ 1.8 | -1.1 % | $ 120 M | USA |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
Cabaletta Bio
CABA
|
254 M | $ 2.94 | -3.29 % | $ 3.43 M | USA |
 |
Iterum Therapeutics
ITRM
|
44.6 M | $ 0.16 | -5.45 % | $ 3.15 M |  Irlanda |
 |
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | USA |